Showing results (581-590 of 688) with videos related to

Sort By:
Pageof 69
Modern Rheumatology|November 7, 2024
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Arthritis Research & Therapy|October 22, 2014
An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3Jane Zochling, Felicity Newell, Jac C Charlesworth, et al.
Rheumatology (Oxford, England)|October 16, 2012
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Nicole Goh, Tamera Corte, et al.
Osteoarthritis and Cartilage Open|December 7, 2022
Predominant lifetime occupation and associations with painful and structural knee osteoarthritis: An international participant-level cohort collaborationCamille M Parsons, Lucy S Gates, Thomas Perry, et al.
Annals of the Rheumatic Diseases|February 21, 2014
The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 studyMarita Cross, Emma Smith, Damian Hoy, et al.
Annals of the Rheumatic Diseases|June 10, 2015
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Annals of the Rheumatic Diseases|August 2, 2013
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Pageof 69